News Article | May 22, 2017
Researchers from Princeton University's Department of Molecular Biology have identified a small RNA molecule that helps maintain the activity of stem cells in both healthy and cancerous breast tissue. The study, which will be published in the June issue of Nature Cell Biology, suggests that this "microRNA" promotes particularly deadly forms of breast cancer and that inhibiting the effects of this molecule could improve the efficacy of existing breast cancer therapies. Stem cells give rise to the different cell types in adult tissues but, in order to maintain these tissues throughout adulthood, stem cells must retain their activity for decades. They do this by "self-renewing," dividing to form additional stem cells, and resisting the effects of environmental signals that would otherwise cause them to prematurely differentiate into other cell types. Many tumors also contain so-called "cancer stem cells" that can drive tumor formation. Some tumors, such as triple-negative breast cancers, are particularly deadly because they contain large numbers of cancer stem cells that self-renew and resist differentiation. To identify factors that help non-cancerous mammary gland stem cells (MaSCs) resist differentiation and retain their capacity to self-renew, Yibin Kang, the Warner-Lambert/Parke-Davis Professor of Molecular Biology, and colleagues searched for short RNA molecules called microRNAs that can bind and inhibit protein-coding messenger RNAs to reduce the levels of specific proteins. The researchers identified one microRNA, called miR-199a, that helps MaSCs retain their stem-cell activity by suppressing the production of a protein called LCOR, which binds DNA to regulate gene expression. The team showed that when they boosted miR-199a levels in mouse MaSCs, they suppressed LCOR and increased normal stem cell function. Conversely, when they increased LCOR levels, they could curtail mammary gland stem cell activity. Kang and colleagues found that miR-199a was also expressed in human and mouse breast cancer stem cells. Just as boosting miR-199a levels helped normal mammary gland stem cells retain their activity, the researchers showed that miR-199a enhanced the ability of cancer stem cells to form tumors. By increasing LCOR levels, in contrast, they could reduce the tumor-forming capacity of the cancer stem cells. In collaboration with researchers led by Zhi-Ming Shao, a professor at Fudan University Shanghai Cancer Center in China, Kang's team found that breast cancer patients whose tumors expressed large amounts of miR-199a showed poor survival rates, whereas tumors with high levels of LCOR had a better prognosis. Kang and colleagues found that LCOR sensitizes cells to the effects of interferon-signaling molecules released from epithelial and immune cells, particularly macrophages, in the mammary gland. During normal mammary gland development, these cells secrete interferon-alpha to promote cell differentiation and inhibit cell division, the researchers discovered. By suppressing LCOR, miR-199a protects MaSCs from interferon signaling, allowing MaSCs to remain undifferentiated and capable of self-renewal. The microRNA plays a similar role during tumorigenesis, protecting breast cancer stem cells from the effects of interferons secreted by immune cells present in the tumor. "This is a very nice study linking a normal and malignant mammary gland stem cell program to protection from immune modulators," said Michael Clarke, the Karel H. and Avice N. Beekhuis Professor in Cancer Biology at Stanford School of Medicine, Institute of Stem Cell Biology and Regenerative Medicine, who first discovered breast cancer stem cells but was not involved in this study. "It clearly has therapeutic implications for designing strategies to rationally target the breast cancer stem cells with immune modulators." Toni Celià -Terrassa, an associate research scholar in the Kang lab and the first author of the study, said, "This study unveils a new property of breast cancer stem cells that give them advantages in their interactions with the immune system, and therefore it represents an excellent opportunity to exploit for improving immunotherapy of cancer." "Interferons have been widely used for the treatment of multiple cancer types," Kang said. "These treatments might become more effective if the interferon-resistant cancer stem cells can be rendered sensitive by targeting the miR-199a-LCOR pathway." Other authors on the paper were Daniel Liu, Abrar Choudhury, Xiang Hang, Yong Wei, Raymundo Alfaro-Aco, Rumela Chakrabarti, Christina DeCoste, Bong Ihn Koh and Heath Smith of the Department of Molecular Biology at Princeton University; Jose Zamalloa of the Department of Molecular Biology and the Lewis-Sigler Institute for Integrative Genomics at Princeton University; and Yi-Zhou Jiang, Jun-Jing Li and Zhi-Ming Shao of the Department of Breast Surgery at Fudan University Shanghai Cancer Center and the Department of Oncology at Shanghai Medical College, Fudan University.
News Article | May 23, 2017
Elizabeth Iorns, Ph.D., Founder and CEO of Science Exchange will present the Reproducibility Project: Cancer Biology PALO ALTO, CA--(Marketwired - May 23, 2017) - Science Exchange, the world's leading marketplace for outsourced research & development, today announced that Elizabeth Iorns, Ph.D., Founder and CEO of Science Exchange has been invited to present at Novartis Institutes for Biomedical Research (NIBR) Seminar. She will present on the Reproducibility Project: Cancer Biology, hosted by Jay Bradner, President of NIBR. The weekly series is an academic seminar series open to the public and externals. Invited speakers are primarily external scientists from academic institutions. Elizabeth Iorns will share her thoughts and recent discoveries on the Reproducibility Project: Cancer Biology on Wednesday, May 31, 2017 from 12:00 - 1:00 p.m. at the NIBR headquarters in Cambridge, Massachusetts. This session will explore the project and initial results, and attendees are invited to join the discussion on whether replication studies could be utilized more frequently as a mechanism to identify qualified targets for further in-house assessment. The Reproducibility Project: Cancer Biology is a collaboration between Science Exchange and the Center for Open Science (COS) to independently replicate key experiments from high-impact published cancer biology studies. The project was initiated in response to multiple reports published from the pharmaceutical industry indicating that more than 70% of published findings could not be reproduced. Science Exchange sourced and project managed the replication experiments for the project which is published in eLife: https://elifesciences.org/collections/reproducibility-project-cancer-biology. "I am honored to speak at NIBR and explore the disruptive topic of reproducibility in our industry," said Dr. Elizabeth Iorns. "Science Exchange and NIBR share a vision to promote the development of science, research and innovation as well as advocate how entrepreneurs can bring about change in this industry." For more information about the event and NIBR Weekly Seminar Series 2017, please visit https://www.eventbrite.com/e/reproducibility-project-cancer-biology-tickets-34259041716 About Science Exchange Science Exchange is the world's leading marketplace for outsourced research. Science Exchange provides an efficient procure-to-pay platform for ordering services from the world's largest network of scientific service providers. Through Science Exchange, clients gain access to 3000+ qualified service providers, all with pre-established contracts in place that protect client intellectual property and confidentiality. This increases scientists access to innovation and significantly improves their productivity because they are freed up from the administrative tasks and delays associated with sourcing, establishing and managing supplier contracts. At an organizational level, the Science Exchange enterprise program enables organizations to consolidate the long tail of research outsourcing spend into a single strategic supplier relationship driving significant efficiency and cost savings. To date, Science Exchange has raised over $30 million from Maverick Capital Ventures, Union Square Ventures, Index Ventures, OATV, the YC Continuity Fund, and others. For more information visit www.scienceexchange.com.
News Article | May 25, 2017
The OHSU Knight Cancer Institute's project aims to develop strategies for improving treatment-resistant triple negative breast cancer, an aggressive form of breast cancer that lacks key receptors known to fuel most breast cancers: estrogen receptors, progesterone receptors and human epidermal growth factor receptor 2 (HER2). Using advanced microscopy, the team will leverage tools for quantitative analysis and visualization of images generated, together with computational approaches for integrating diverse molecular data types. Through analysis of core cell lines, patient-derived cultures and primary tumors, the team aims to uncover molecular networks that underlie disease progression and therapeutic response. Joe Gray, Ph.D., director of the OHSU Center for Spatial Systems Biomedicine (OCSSB) and the OHSU Knight Cancer Institute associate director for biophysical oncology will lead the investigative team as a principal investigator. "Triple negative breast cancer is a particularly difficult form of the disease to treat," said Gray. "Our goals in the CSBC Research Center are to identify the mechanisms by which these cancers evolve and adapt to become resistant to treatment, and to develop new strategies to counter these mechanisms. Our multidisciplinary approach treats these cancers as adaptive systems that can be controlled using multiple drug combinations." Co-principal investigators on the project include: Rosalie Sears, Ph.D., professor of molecular and medical genetics in the OHSU School of Medicine and a senior member of the Knight Cancer Institute; Claire Tomlin, Ph.D., the Charles A. Desoer Professor of Engineering in the Department of Electrical Engineering and Computer Sciences at the University of California, Berkeley; Adam Margolin, Ph.D., associate professor of biomedical engineering and director of computational biology in the OHSU School of Medicine and the Knight Cancer Institute. Overall research themes of the consortium's Research Centers address important questions in basic cancer research, including the emergence of drug resistance, the mechanisms underlying cancer metastasis, and the role of the immune system in cancer progression and treatment. The interdisciplinary investigators of the CSBC will integrate experimental biology with mathematical and computational modeling to gain insight into processes relevant to cancer initiation, progression and treatment options. The consortium brings together clinical and basic science cancer researchers with physician-scientists, engineers, mathematicians and computer scientists to tackle key questions in cancer biology from a novel point of view. "Cancer is a complex disease and it challenges our traditional approaches, making it hard to predict tumor growth and drug response," said Daniel Gallahan, Ph.D., deputy director of NCI's Division of Cancer Biology. "Cancer systems biologists embrace that complexity and use many different types of data to build mathematical models that allow us to make predictions about whether a tumor will metastasize or what drug combinations will be effective." In addition to applying systems biology approaches to gain important insight into cancer, each consortium Research Center supports an outreach program to promote training in interdisciplinary science, disseminate important research findings to the community, and to engage the public in cancer systems biology research. Sage Bionetworks in Seattle serves as the consortium's Coordinating Center, facilitating data and resource sharing and collaborative scientific activities across the nine Research Centers as well as two new Research Projects. More information can be found on the project website. The Knight Cancer Institute at Oregon Health & Science University is a pioneer in the field of precision cancer medicine. The institute's director, Brian Druker, M.D., helped prove it was possible to shut down just the cells that enable cancer to grow. This breakthrough has made once-fatal forms of the disease manageable and transformed how cancer is treated. The OHSU Knight Cancer Institute is the only National Cancer Institute-designated Cancer Center between Sacramento and Seattle – an honor earned only by the nation's top cancer centers. It is headquarters for one of the National Cancer Institute's largest research collaboratives, SWOG, in addition to offering the latest treatments and technologies as well as hundreds of research studies and clinical trials. For additional information on the OHSU Knight Cancer Institute visit www.ohsu.edu/xd/health/services/cancer or follow us on Facebook and Twitter. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ohsu-knight-cancer-institute-selected-to-join-prestigious-national-consortium-receive-92-million-300464180.html
News Article | April 21, 2017
Collaboration will allow OCB's suite of precision oncology In Vitro Diagnostic tests to be rolled out across the People's Republic of China OXFORD, England, April 18, 2017 /PRNewswire/ -- Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be personalised for the benefit of the cancer patient, has today announced a strategic collaboration with My-BioMed Biotechnology Ltd. based in Ningbo, Zhejiang, China. Oxford Cancer Biomarkers announces strategic collaboration with My-BioMed Biotechnology Ltd. The partnership includes a licencing deal that will allow My-BioMed Biotechnology Ltd. to access OCB's ColoTox, ColoProg and ColoPredict technologies and to drive uptake across the PRC via a purpose built biomedical laboratory in Ningbo Meishan FTZ. OCB has developed a suite of diagnostic tests for colorectal cancer (CRC) to personalise current treatment pathways and plans to develop similar tests for other cancer indications. As of 2015, 274,000 new cases of colorectal cancer are diagnosed every year in the People's Republic of China, 190,400 of these cases prove fatal. My-BioMed (MBM) is a leading precision medicine organisation which focused on bringing global innovation to the Chinese market. The team at MBM has extensive experience in product development and launch including clinical development, regulatory strategy, clinical laboratory services, sales and marketing. MBM's core business model is driven by patient and clinician needs. Jackson Zhu, CEO of MBM, commented "We are very happy to launch the first three proprietary CRC diagnostic tests discovered at Oxford University and developed by OCB, aimed at specifically benefitting patients in China. Both MBM and OCB have solidified through this partnership, a long-term commitment to China, with the aim of developing and launching a suite of unique diagnostic products." Prof David Kerr, Chief Medical Officer of OCB, commented "Our strategic partnership with MBM will allow patients across China to access OCB's suite of precision oncology diagnostic technologies. We are looking forward to working closely with MBM to tailor our offerings to the specific needs of the Chinese market and building a robust product pipeline of diagnostics specifically aimed at the Chinese population. This is an important step in our mission to drive global access to technologies that allow patient stratification and individually tailored treatment pathways." About Oxford Cancer Biomarkers Oxford Cancer Biomarkers translates ground-breaking scientific discovery into predictive biomarker diagnostic products that allow medicines to be personalised for the benefit of the cancer patient. Oxford Cancer Biomarkers is a spin-out of the University of Oxford and has strong links with the Medical Sciences Division in Oxford University. The company was founded by Nick La Thangue, Ph.D., Chair of Cancer Biology at Oxford University and David Kerr, CBE, D.Sc., M.D. FMedSci, Professor of Cancer Medicine at Oxford University. Investors in OCB include Longwall Venture Partners LLP, Esperante BV and the University. For more information, please visit: http://www.oxfordcancerbiomarkers.com Contact detailsOxford Cancer Biomarkers Ltd Tel: +44 1865 784743Prof.Nick La Thangue, CEO / David Oxlade, Chairman About Ningbo My-BioMed Biotechnology Co.,Ltd. In pursuit of its vision of "Bridging World Innovation in Precision Medicine", My-BioMed (MBM) is dedicated to providing personalized solutions to clinicians and patients, and to building an integrated commercialization platform for innovation. Supported by Ningbo Meishan's Healthcare industry development strategy, MBM, established in May 2016, has attracted a group of talented individuals with experience across a range of disciplines including business development, market access, clinical development, registration, clinical lab services, sales and marketing. Located at Ningbo Meishan Free Trade Port, My-BioMed Clinical Laboratory, MBM wholly owned subsidiary, has been granted pre-approval from the Health and Family Plan Commission, and will be certified within this year. Ningbo My-BioMed Biotechnology Co.,Ltd. E-Mail：email@example.com CEO: Jackson Zhu Photo - http://photos.prnasia.com/prnh/20170414/1826123-1
News Article | April 27, 2017
Raisa Ahmad was previously a summer associate with the firm, in which she conducted research and prepared memos for patent litigation cases involving software and security patents, pharmaceuticals, and biomedical devices. In addition, she has experience preparing claim construction charts, invalidity contentions, and Lanham Act standing memos. Prior to law school, she was a student engineer and conducted electric-cell substrate impedance sensing analysis for the Center for the Convergence of Physical and Cancer Biology. Ahmad received her J.D. from the University of Arizona College of Law in 2016 where she was senior articles editor for the Arizona Law Review and received the Dean's Achievement Award Scholarship. She received her B.S.E., magna cum laude, in biomedical engineering from Arizona State University in 2011. She is admitted to practice in Texas. Brian Apel practices patent litigation, including post-grant proceedings before the U.S. Patent and Trademark Office. He has worked for clients in the mechanical, electrical, and chemical industries and has experience in pre-suit diligence including opinion work, discovery, damages, summary judgment, and appeals. Apel also has experience in patent prosecution, employment discrimination, and First Amendment law. Before law school, he served as an officer in the U.S. Navy. Apel received his J.D., magna cum laude, Order of the Coif, from the University of Michigan Law School in 2016 and his B.A., with honors, in chemistry from Northwestern University in 2008. He is admitted to practice in Minnesota, the U.S. District Court of Minnesota, and before the U.S. Patent and Trademark Office. Zoya Kovalenko Brooks focuses her practice on patent litigation, including working on teams for one of the largest high-tech cases in the country pertaining to data transmission and memory allocation technologies. She was previously a summer associate and law clerk with the firm. While in law school, she served as a legal extern at The Coca-Cola Company in the IP group. Prior to attending law school, she was an investigator intern at the Equal Employment Opportunity Commission, where she investigated over 20 potential discrimination cases. Brooks received her J.D., high honors, Order of the Coif, from Emory University School of Law in 2016 where she was articles editor for Emory Law Journal and her B.S., high honors, in applied mathematics from the Georgia Institute of Technology in 2013. She is admitted to practice in Georgia. Holly Chamberlain focuses on patent prosecution in a variety of areas including the biomedical, mechanical, and electromechanical arts. She was previously a summer associate with the firm. She received her J.D. from Boston College Law School in 2016 where she was an editor of Intellectual Property and Technology Forum and her B.S. in biological engineering from Massachusetts Institute of Technology in 2013. She is admitted to practice in Massachusetts and before the U.S. Patent and Trademark Office. Thomas Chisena previously was a summer associate with the firm where he worked on patent, trade secret, and trademark litigation. Prior to attending law school, he instructed in biology, environmental science, and anatomy & physiology. Chisena received his J.D., magna cum laude, from the University of Pennsylvania Law School in 2016 where he was executive editor of Penn Intellectual Property Group Online and University of Pennsylvania Journal of International Law, Vol. 37. He also received his Wharton Certificate in Business Management in December 2015. He received his B.S. in biology from Pennsylvania State University in 2009. He is admitted to practice in Pennsylvania, Massachusetts, and the U.S. District Court of Massachusetts. Claire Collins was a legal intern for the Middlesex County District Attorney's Office during law school. She has experience researching and drafting motions and legal memorandums. Collins received her J.D. from the University of Virginia School of Law in 2016 where she was a Dillard Fellow, her M.A. from Texas A&M University in 2012, and her B.A. from Bryn Mawr College in 2006. She is admitted to practice in Massachusetts. Ronald Golden, III previously served as a courtroom deputy to U.S. District Judge Leonard P. Stark and U.S. Magistrate Judge Mary Pat Thynge. He received his J.D. from Widener University School of Law in 2012 where he was on the staff of Widener Law Review and was awarded "Best Overall Competitor" in the American Association for Justice Mock Trial. He received his B.A. from Stockton University in political science and criminal justice in 2005. He is admitted to practice in Delaware and New Jersey. Dr. Casey Kraning-Rush was previously a summer associate with the firm, where she focused primarily on patent litigation. She received her J.D. from the University of Pennsylvania Law School in 2016 where she was managing editor of Penn Intellectual Property Group Online and awarded "Best Advocate" and "Best Appellee Brief" at the Western Regional of the AIPLA Giles Rich Moot Court. She earned her Ph.D. in biomedical engineering from Cornell University in 2013 and has extensive experience researching cellular and molecular medicine. She received her M.S. in biomedical engineering from Cornell University in 2012 and her B.S., summa cum laude, in chemistry from Butler University in 2008. She is admitted to practice in Delaware. Alana Mannigé was previously a summer associate with the firm and has worked on patent prosecution, patent litigation, trademark, and trade secret matters. During law school, she served as a judicial extern to the Honorable Judge James Donato of the U.S. District Court for the Northern District of California. She also worked closely with biotech startup companies as part of her work at the UC Hastings Startup Legal Garage. Prior to attending law school, Mannigé worked as a patent examiner at the U.S. Patent and Trademark Office. She received her J.D., magna cum laude, from the University of California, Hastings College of the Law in 2016 where she was senior articles editor of Hastings Science & Technology Law Journal. She received her M.S. in chemistry from the University of Michigan in 2010 and her B.A., cum laude, in chemistry from Clark University in 2007. She is admitted to practice in California and before the U.S. Patent and Trademark Office. Will Orlady was previously a summer associate with the firm, in which he collaborated to research and brief a matter on appeal to the Federal Circuit. He also analyzed novel issues related to inter partes review proceedings, drafted memoranda on substantive patent law issues, and crafted infringement contentions. During law school, Orlady was a research assistant to Professor Kristin Hickman, researching and writing on administrative law. He received his J.D., magna cum laude, Order of the Coif, from the University of Minnesota Law School in 2016 where he was lead articles editor of the Minnesota Journal of Law, Science and Technology and his B.A. in neuroscience from the University of Southern California in 2012. He is admitted to practice in Minnesota and the U.S. District Court of Minnesota. Jessica Perry previously was a summer associate and law clerk with the firm, where she worked on patent and trademark litigation. During law school, she was an IP & licensing analyst, in which she assisted with drafting and tracking material transfer agreement and inter-institutional agreements. She also worked with the Boston University Civil Litigation Clinic representing pro bono clients with unemployment, social security, housing, and family law matters. Prior to law school, she was a senior mechanical design engineer for an aerospace company. She received her J.D. from Boston University School of Law in 2016 where she was articles editor of the Journal of Science and Technology Law, her M.Eng. in mechanical engineering from Rensselaer Polytechnic Institute in 2009, and her B.S. in mechanical engineering from the University of Massachusetts, Amherst in 2007. She is admitted to practice in Massachusetts and the U.S. District Court of Massachusetts. Taufiq Ramji was previously a summer associate with the firm, in which he researched legal issues that related to ongoing litigation and drafted responses to discovery requests and U.S. Patent and Trademark Office actions. Prior to attending law school, Ramji worked as a software developer. He received his J.D. from Harvard Law School in 2016. He is admitted to practice in California. Charles Reese has worked on matters before various federal district courts, the Court of Appeals for the Federal Circuit, and the Patent Trial and Appeal Board. His litigation experience includes drafting dispositive, evidentiary, and procedural motions; arguing in federal district court; and participating in other stages of litigation including discovery, appeal, and settlement negotiation. Previously, he was a summer associate with the firm. He received his J.D., cum laude, from Harvard Law School in 2016 where he was articles editor of Harvard Law Review, his A.M. in organic and organometallic chemistry from Harvard University in 2012, and his B.S., summa cum laude, in chemistry from Furman University in 2010. He is admitted to practice in Georgia and the U.S. District Court for the Northern District of Georgia. Ethan Rubin was previously a summer associate and law clerk with the firm. During law school, he worked at a corporation's intellectual property department in which he prepared and prosecuted patents relating to data storage systems. He also worked as a student attorney, advocating for local pro bono clients on various housing and family law matters. Rubin received his J.D., cum laude, from Boston College Law School in 2016 where he was articles editor of Boston College Law Review, his M.S. in computer science from Boston University in 2013, and his B.A., magna cum laude, in criminal justice from George Washington University in 2011. He is admitted to practice in Massachusetts and before the U.S. Patent and Trademark Office. Pooya Shoghi focuses on patent prosecution, including portfolio management, application drafting, client counseling, and standard essential patent development. Prior to joining the firm, he was a patent practitioner at a multinational technology company, where he was responsible for the filing and prosecution of U.S. patent applications. During law school, he was a legal intern at a major computer networking technology company, where he focused on issues of intellectual property licensing in the software arena. He received his J.D., with honors, from Emory University School of Law in 2014 where he was executive managing editor of Emory Corporate Governance and Accountability Review. He received his B.S., summa cum laude, in computer science (2015) and his B.A., summa cum laude, in political science (2011) from Georgia State University. He is admitted to practice in New York and before the U.S. Patent and Trademark Office. Tucker Terhufen focuses his practice on patent litigation in federal district courts as well as before the International Trade Commission for clients in the medical devices, life sciences, chemical, and electronics industries. Prior to joining Fish, he served as judicial extern to the Honorable David G. Campbell of the U.S. District Court for the District of Arizona and to the Honorable Mary H. Murguia of the U.S. Court of Appeals for the Ninth Circuit. He received his J.D., magna cum laude, Order of the Coif, from Arizona State University, Sandra Day O'Connor College of Law in 2016 where he was note and comment editor of Arizona State Law Journal and received a Certificate in Law, Science, and Technology with a specialization in Intellectual Property. He received his B.S.E., summa cum laude, in chemical engineering from Arizona State University. He is admitted to practice in California. Laura Whitworth was previously a summer associate with the firm. During law school, she served as a judicial intern for the Honorable Judge Jimmie V. Reyna of the U.S. Court of Appeals for the Federal Circuit. She received her J.D., cum laude, from American University Washington College of Law in 2016 where she was senior federal circuit editor of American University Law Review and senior patent editor of Intellectual Property Brief. She received her B.S. in chemistry from the College of William & Mary in 2013. She is admitted to practice in Virginia, the U.S. District Court for the Eastern District of Virginia, and before the U.S. Patent and Trademark Office. Jack Wilson was previously a summer associate with the firm. During law school, he served as a judicial extern for the Honorable Mark Davis of the United States District Court for the Eastern District of Virginia. Prior to attending law school, he served in the United States Army. He received his J.D., magna cum laude, from William & Mary Law School in 2016 where he was on the editorial staff of William & Mary Law Review and his B.S. in computer engineering from the University of Virginia in 2009. He is admitted to practice in Virginia and before the U.S. Patent and Trademark Office. Fish & Richardson is a global patent prosecution, intellectual property litigation, and commercial litigation law firm with more than 400 attorneys and technology specialists in the U.S. and Europe. Our success is rooted in our creative and inclusive culture, which values the diversity of people, experiences, and perspectives. Fish is the #1 U.S. patent litigation firm, handling nearly three times as many cases than its nearest competitor; a powerhouse patent prosecution firm; a top-tier trademark and copyright firm; and the #1 firm at the Patent Trial and Appeal Board, with more cases than any other firm. Since 1878, Fish attorneys have been winning cases worth billions in controversy – often by making new law – for the world's most innovative and influential technology leaders. For more information, visit https://www.fr.com or follow us at @FishRichardson. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/fish--richardson-announces-18-recent-associates-300447237.html
News Article | May 8, 2017
PHILADELPHIA - A newly identified molecular chain of events in a mouse model of prostate cancer highlights novel targets to treat it and other cancers. A team led by Marcelo Kazanietz, PhD, a professor of Systems Pharmacology and Translational Therapeutics, published in Cell Reports that the overexpression of a protein called PKCε with the loss of the tumor suppressor Pten causes the progression of prostate cancer. This deadly combination produces an uptick in the levels of the cancer-promoting molecule CXCL13. When the team purposely disrupted CXCL13, or CXCR5, the cell-surface receptor it attaches to, the metastatic and tumor-forming characteristics of the mouse prostate cancer cells were impaired. "In addition to providing evidence for a vicious cancer cycle driven by PKCε, our studies identified a compelling rationale for blocking the CXCL13-CXCR5 molecules as a new cancer treatment," Kazanietz said. He and colleagues plan to identify compounds to block CXCR5 or CXCL13 with potential to be developed as anti-cancer agents. The researchers also suggested that CXCL13 levels in blood could be used as a biomarker to measure the precise state of prostate cancer progression in a patient. The team's next step will be to interfere with CXCR5/CXCL13 signals not only from the cancer cells but also from other cells in the tumor microenvironment that contribute to cancer growth. Pulmonologists and oncologists have also observed that PKCε is overexpressed in lung cancer patients, but they do not fully understand its exact molecular consequences. In general, a high level of PKCε is associated with a poor prognosis. "We are in the midst of extending these findings to lung cancer," said Kazanietz, who is collaborating with Penn Medicine researchers David Feldser, PhD, an assistant professor of Cancer Biology, Steven M. Albelda, MD, a professor of Pulmonary, Allergy and Critical Care, and Evgeniy Eruslanov, PhD, a research assistant professor of Thoracic Surgery. This research was funded in part by the National Institutes of Health (R01-CA089202, R01-CA189765, R01-CA196232), the Department of Defense (PC130641, W81XWH-12-1-0009). Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $6.7 billion enterprise. The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $392 million awarded in the 2016 fiscal year. The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center -- which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report -- Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine. Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2016, Penn Medicine provided $393 million to benefit our community.
News Article | February 28, 2017
CINCINNATI--Researchers at the University of Cincinnati (UC) College of Medicine have discovered a new potential strategy to personalize therapy for brain and blood cancers. These findings are reported in the Feb. 28 edition of Cell Reports. "We found a new combination of therapeutics that could treat cancers that lack a protein called PTEN. PTEN is an important tumor suppressor, which means that it stops cell growth and division according to the needs of the body," says David Plas, PhD, Anna and Harold W. Huffman Endowed Chair for Glioblastoma Experimental Therapeutics. Plas is an associate professor in the Department of Cancer Biology, a member of the University of Cincinnati Cancer Institute and a researcher in the Brain Tumor Center of the UC Gardner Neuroscience Institute. Atsuo Sasaki, PhD, and Hala Elnakat Thomas, PhD, both in the Division of Hematology Oncology at the UC College of Medicine, were collaborators on the study. In early work using experimental therapeutics in human cancer cells and in tumor models, the Plas laboratory showed that stopping the production and function of the protein S6K1 could eliminate PTEN-deficient glioblastoma cells. Glioblastoma, the most aggressive form of brain cancer, is difficult to treat with targeted therapeutics. "We used support from the Huffman Foundation to conduct a sophisticated biochemical analysis of how cells respond to S6K1 targeting," Plas says. "Combining the biochemical results with computational analysis gave us the insight that we needed--there are targets in addition to S6K1 that can be hit to trigger the elimination of PTEN-deficient cancer cells." With the new information, the research team tested pharmaceutical-grade drug combinations for the ability to eliminate PTEN-deficient cancer cells. Results showed that the drugs LY-2779964 and BMS-777607 work together to specifically eliminate PTEN-deficient cells. "This is a completely new combination of targets in oncology," Plas says. "We have great hope that our new data will lead academic and industry researchers to investigate S6K1 as the center of new combination strategies for cancers of the brain, blood and other tissues." Future work in the project will test the safety and efficacy of the new combination using tumor models, with the goal of preparing the combination strategy for clinical trial. Ronald Warnick, MD, medical director of the UC Brain Tumor Center and a professor in the Department of Neurosurgery within the UC College of Medicine, adds that this kind of project is necessary in finding new and beneficial therapies for brain tumors. "There is a desperate need for novel therapeutic agents for patients with glioblastoma," he says. "This combination of drugs has the potential to become a game-changer." This study was funded by the American Cancer Society, the National Institutes of Health (R01 CA133164, R01 CA168815, R21NS100077, R01NS089815), the UC Brain Tumor Center, the Anna and Harold W. Huffman Endowed Chair for Glioblastoma Experimental Therapeutics and the UC Medical Scientist Training Program. Plas cites no conflict of interest.